

Agenda released for Drug Discovery 2017

Big pharma and biotech aim to bridge gaps at Drug Discovery 2017 in London in March

LONDON, SELECT ONE, UNITED KINGDOM, October 28, 2016 /EINPresswire.com/ -- The gap between a laboratory discovery and an approved drug on the market is a decade-long process of laboratory testing, evaluation in animal models, and human clinical trials that can cost hundreds of millions. Against this backdrop, SMi Group has launched [Drug Discovery 2017](http://www.drug-discovery.co.uk), which aims to bridge the gaps in approval for drug discovery and development through the latest scientific breakthroughs, novel technologies and approaches that can defeat drug development challenges.

Taking place on the 27th and 28th of March 2017 in Central London, [the two-day event](#) will gather industry leaders who will highlight future opportunities for novel therapeutic discovery. Registration is now live.

The expert speaker panel includes:

- Lorenz Mayr, VP & Global Head, AstraZeneca
- Guido Hanaeur, Scientific Director Translational Medicine, Takeda
- Ulrich Schopfer, Executive Director,

Head Integrated Lead Discovery, Novartis

- Yolanda Chong, Principal Scientist, Johnson & Johnson
- Matthias Frech, Director, Molecular Interactions & Biophysics, Merck Serono
- Wengard Czechtizky, Head of Chemistry, Sanofi
- Ulrich Schopfer, Executive Director, head Integrated Lead Discovery, Novartis
- Stephen Pickett, Senior Scientific Investigator, GSK

Plus more from AbbVie, UCB Pharma, Eli Lilly, TissUse, Heptares.

Key Highlights of the show include:

- discussions on the use of CRISPR/Cas9 Technology in target discovery, hit finding and translational



Drug Discovery 27-28 March



Drug Discovery 2017 Brochure

studies;

- success stories on phenotyping screening;
- debates on whether translational medicine is capable of increasing success rate in pharma;
- insights into receptor activation from agonist and antagonist structures;
- applications of enabling chemistry technology to the acceleration of the drug discovery process

and more. The full agenda and list of speakers can be found on the [event website](#).

For more details about the conference and registration information, visit www.drug-discovery.co.uk/EIN.

DRUG DISCOVERY

27-28 March 2017

Holiday Inn Kensington Forum, London, UK

www.drug-discovery.co.uk/EIN

---end ---

Contact Information:

For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Matthew Apps at mapps@smi-online.co.uk. For media queries please contact Honey de Gracia at hdegracia@smi-online.co.uk.

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Honey de Gracia
SMi Group Ltd
+44 (0)20 7827 6102
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.